IS8920A - 3-(Fenýl eða kínólyl)þíó- 1H-idnól-1-ediksýru afleður sem mótarar á virkni CRTh2 vitaka. - Google Patents

3-(Fenýl eða kínólyl)þíó- 1H-idnól-1-ediksýru afleður sem mótarar á virkni CRTh2 vitaka.

Info

Publication number
IS8920A
IS8920A IS8920A IS8920A IS8920A IS 8920 A IS8920 A IS 8920A IS 8920 A IS8920 A IS 8920A IS 8920 A IS8920 A IS 8920A IS 8920 A IS8920 A IS 8920A
Authority
IS
Iceland
Prior art keywords
idanol
quinolyl
thio
phenyl
activity
Prior art date
Application number
IS8920A
Other languages
English (en)
Inventor
Roger Bonnert
Rukshana Mohammed
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8920A publication Critical patent/IS8920A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8920A 2003-05-27 2010-08-09 3-(Fenýl eða kínólyl)þíó- 1H-idnól-1-ediksýru afleður sem mótarar á virkni CRTh2 vitaka. IS8920A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301569A SE0301569D0 (sv) 2003-05-27 2003-05-27 Novel compounds
SE0302305A SE0302305D0 (sv) 2003-05-27 2003-08-27 Novel Compounds

Publications (1)

Publication Number Publication Date
IS8920A true IS8920A (is) 2010-08-09

Family

ID=33492578

Family Applications (2)

Application Number Title Priority Date Filing Date
IS8189A IS2722B (is) 2003-05-27 2005-12-20 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
IS8920A IS8920A (is) 2003-05-27 2010-08-09 3-(Fenýl eða kínólyl)þíó- 1H-idnól-1-ediksýru afleður sem mótarar á virkni CRTh2 vitaka.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS8189A IS2722B (is) 2003-05-27 2005-12-20 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum

Country Status (31)

Country Link
US (4) US7687535B2 (is)
EP (3) EP2281815B1 (is)
JP (2) JP4541361B2 (is)
KR (3) KR101067535B1 (is)
CN (2) CN1795174B (is)
AR (1) AR044552A1 (is)
AT (3) ATE552243T1 (is)
AU (1) AU2004242624B2 (is)
BR (1) BRPI0410711B8 (is)
CA (1) CA2526866C (is)
CO (1) CO5630030A2 (is)
CY (3) CY1109104T1 (is)
DE (2) DE602004031894D1 (is)
DK (3) DK2025670T3 (is)
ES (3) ES2382606T3 (is)
HK (3) HK1090635A1 (is)
HR (3) HRP20090281T1 (is)
IL (4) IL171928A (is)
IS (2) IS2722B (is)
MX (1) MXPA05012680A (is)
MY (1) MY144483A (is)
NO (1) NO20056130L (is)
NZ (1) NZ543722A (is)
PL (3) PL2025670T3 (is)
PT (3) PT1656346E (is)
RU (1) RU2361860C2 (is)
SE (2) SE0301569D0 (is)
SI (3) SI1656346T1 (is)
TW (2) TWI328004B (is)
WO (1) WO2004106302A1 (is)
ZA (1) ZA200509598B (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
KR100808742B1 (ko) 2004-03-11 2008-02-29 액테리온 파마슈티칼 리미티드 테트라하이드로피리도인돌 유도체
AU2005320964B2 (en) 2004-12-27 2011-12-15 Actelion Pharmaceuticals Ltd. 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
WO2006111560A2 (en) 2005-04-21 2006-10-26 Laboratoires Serono S.A. 2,3 substituted pyrazine sulfonamides as inhibitors of crth2
EP1891075B1 (en) 2005-05-24 2011-10-19 Merck Serono SA Tricyclic spiro derivatives as crth2 modulators
JP5072594B2 (ja) 2005-07-22 2012-11-14 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するインドール誘導体
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Ｐｇｄ2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
NZ566537A (en) * 2005-09-30 2010-10-29 Pulmagen Therapeutics Asthma L Quinolines and their therapeutic use
US7741360B2 (en) 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
HUE030850T2 (en) 2006-06-16 2017-06-28 Univ Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of hair loss
SI2046740T1 (sl) * 2006-07-22 2012-12-31 Oxagen Limited Spojine s crth2 antagonistiäśno aktivnostjo
NZ574705A (en) 2006-08-07 2011-12-22 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
JP6006914B2 (ja) * 2007-06-21 2016-10-12 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストのアミン塩
RU2468012C2 (ru) * 2007-06-21 2012-11-27 Актимис Фармасьютикалз, Инк. Частицы антагониста crth2
MX2010006341A (es) 2007-12-14 2010-08-02 Pulmagen Therapeutics Asthma L Indoles y su uso terapeutico.
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US20110312945A1 (en) * 2008-10-01 2011-12-22 James Jia Crth2 modulators
AU2010212970A1 (en) 2009-02-12 2011-08-18 Merck Serono S.A. Phenoxy acetic acid derivatives
AU2010270050B9 (en) * 2009-07-06 2013-06-27 Astrazeneca Ab Intermediates and processes for the preparation of 4- (acetylamino) ) -3- [ (4-chloro-phenyl) thio] -2-methyl-1H-indole-1-acetic acid
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
US9032565B2 (en) 2009-12-16 2015-05-19 Kohler Co. Touchless faucet assembly and method of operation
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
UA110245C2 (en) 2011-04-14 2015-12-10 Actelion Pharmaceuticals Ltd 7-(heleroaryl-amino)-6,7,8,9-letrahydropyrido[1,2-a]indol acetic acid derivatives and their application as prostaglandin d2 receptor modulators
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
KR102205774B1 (ko) 2012-03-21 2021-01-20 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 모발 성장을 조절하는 방법 및 조성물
WO2014055595A1 (en) * 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
ES2688575T3 (es) 2013-03-15 2018-11-05 Plexxikon Inc. Compuestos heterocíclicos y sus usos
CN105473578A (zh) * 2013-05-24 2016-04-06 加州生物医学研究所 用于治疗抗药性和持续性结核病的化合物
BR112016021471B1 (pt) 2014-03-17 2022-10-11 Idorsia Pharmaceuticals Ltd Compostos derivados de ácido acético azaindol, composição farmacêutica, e, uso de um composto
US9850241B2 (en) 2014-03-18 2017-12-26 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
KR20180031019A (ko) 2015-07-30 2018-03-27 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｐｇｄ２에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 ｄｐ―２ 유전자의 단일 뉴클레오티드 다형성 대립유전자
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
CA2156420A1 (en) 1993-02-24 1994-09-01 Theresa M. Williams Inhibitors of hiv reverse transcriptase
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA987554B (en) 1997-08-21 2000-02-21 American Home Prod Methods for the solid phase synthesis of substituted indole compounds.
EP0924209B1 (en) 1997-12-19 2003-05-02 Eli Lilly And Company Hypoglycemic imidazoline compounds
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
WO2001032621A1 (fr) * 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif
CA2699568C (en) 1999-12-24 2013-03-12 Aventis Pharma Limited Azaindoles
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
AU2001266232B2 (en) 2000-07-07 2005-09-15 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
JP4595182B2 (ja) * 2000-09-07 2010-12-08 ソニー株式会社 情報記録装置、情報再生装置、情報記録方法、情報再生方法、および情報記録媒体、並びにプログラム提供媒体
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
AU2003218962B2 (en) 2002-02-01 2008-09-25 F. Hoffmann-La Roche Ag Substituted indoles as alpha-1 agonists
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP2423190A1 (en) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
EP1675826A1 (en) * 2003-10-14 2006-07-05 Oxagen Limited Compounds having crth2 antagonist activity
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
US7741360B2 (en) 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
BRPI0712139A2 (pt) 2006-06-08 2012-01-10 Neurokey As uso de agonistas receptores de canabinóide como fármacos indutores de hipotermia para o tratamento da isquemia
JP5237938B2 (ja) 2006-06-28 2013-07-17 サノフイ 新規なｃｘｃｒ２阻害剤

Also Published As

Publication number Publication date
HRP20120390T1 (hr) 2012-06-30
ES2322650T3 (es) 2009-06-24
IS2722B (is) 2011-03-15
SE0301569D0 (sv) 2003-05-27
WO2004106302A1 (en) 2004-12-09
TWI328004B (en) 2010-08-01
ES2382606T3 (es) 2012-06-11
ZA200509598B (en) 2006-12-27
HRP20090281T1 (en) 2009-06-30
DK2281815T3 (da) 2012-06-18
US20080249110A1 (en) 2008-10-09
US7687535B2 (en) 2010-03-30
JP2007501269A (ja) 2007-01-25
US20090163518A1 (en) 2009-06-25
MXPA05012680A (es) 2006-02-08
CN1795174A (zh) 2006-06-28
EP2025670B1 (en) 2011-03-16
PL1656346T3 (pl) 2009-07-31
SI2025670T1 (sl) 2011-06-30
ATE425965T1 (de) 2009-04-15
CY1109104T1 (el) 2014-07-02
EP2025670A1 (en) 2009-02-18
CA2526866C (en) 2012-10-16
HK1090635A1 (en) 2006-12-29
KR20060015303A (ko) 2006-02-16
CN1795174B (zh) 2011-09-28
CY1111469T1 (el) 2015-08-05
CN102391171A (zh) 2012-03-28
DE602004031894D1 (de) 2011-04-28
JP2010155862A (ja) 2010-07-15
US20110263614A1 (en) 2011-10-27
RU2005137403A (ru) 2006-05-27
ATE552243T1 (de) 2012-04-15
EP2281815B1 (en) 2012-04-04
JP4541361B2 (ja) 2010-09-08
HRP20110359T1 (hr) 2011-06-30
DK2025670T3 (da) 2011-06-06
CA2526866A1 (en) 2004-12-09
DK1656346T3 (da) 2009-06-15
PT2281815E (pt) 2012-05-24
KR101067535B1 (ko) 2011-09-27
CY1112853T1 (el) 2016-02-10
IS8189A (is) 2005-12-20
CO5630030A2 (es) 2006-04-28
PT1656346E (pt) 2009-05-20
BRPI0410711B1 (pt) 2018-09-25
AU2004242624A1 (en) 2004-12-09
HK1126773A1 (is) 2009-09-11
BRPI0410711A (pt) 2006-06-13
SI2281815T1 (sl) 2012-06-29
NZ543722A (en) 2007-05-31
US20120178764A1 (en) 2012-07-12
IL194872A0 (en) 2011-08-01
IL212265A0 (en) 2011-06-30
RU2361860C2 (ru) 2009-07-20
MY144483A (en) 2011-09-30
DE602004020072D1 (de) 2009-04-30
PL2025670T3 (pl) 2011-07-29
SI1656346T1 (sl) 2009-08-31
TW200510301A (en) 2005-03-16
BRPI0410711B8 (pt) 2021-05-25
AU2004242624B2 (en) 2008-03-13
SE0302305D0 (sv) 2003-08-27
ATE502010T1 (de) 2011-04-15
KR20110051297A (ko) 2011-05-17
IL212371A0 (en) 2011-06-30
IL171928A (en) 2011-06-30
NO20056130L (no) 2006-02-27
KR20110050754A (ko) 2011-05-16
PL2281815T3 (pl) 2012-08-31
EP2281815A1 (en) 2011-02-09
ES2361485T3 (es) 2011-06-17
EP1656346B1 (en) 2009-03-18
HK1149563A1 (is) 2011-10-07
PT2025670E (pt) 2011-05-24
IL171928A0 (en) 2006-04-10
EP1656346A1 (en) 2006-05-17
TW201024261A (en) 2010-07-01
KR101067586B1 (ko) 2011-09-27
AR044552A1 (es) 2005-09-21

Similar Documents

Publication Publication Date Title
IS8920A (is) 3-(Fenýl eða kínólyl)þíó- 1H-idnól-1-ediksýru afleður sem mótarar á virkni CRTh2 vitaka.
LU92504I2 (fr) Fluopyram
DE60316104D1 (de) Selbstausrichtender drehbarer Aufhängehaken
IS7607A (is) Ný útskipt indól
IS8439A (is) Nýjar kínólín afleiður
DE602006018392D1 (de) Veränderung der IEEE 802.11e EDCA Zulassungssteuerungsparameter
IS8352A (is) Ný rópínírólsamsetning
NL1025839A1 (nl) Chinoline- en chinoxalineverbindingen.
ITTO20010883A0 (it) Pista sospesa.
DE60322340D1 (de) Riechstoffverbindung
ATE416317T1 (de) Flanschverbindung
DE60312706D1 (de) Wachsbeschichterer Käse
DK1536783T3 (da) Faste formuleringer, der omfatter en indolinonforbindelse
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
ITMI20022704A1 (it) Procedimento per la produzione di mesitilene e durene.
IS7609A (is) 2,5-tvíútskipt 3-merkaptópentansýra
DK1480970T3 (da) Quinolinderivater
ITBZ20040033A1 (it) Impianto di rilevamento dell'umidita'.
ITMI20021328A1 (it) Nuove piperazine 1,4 - disostituite
ES1052266Y (es) Comedero para animales.
ES1055573Y (es) Cortacesped.
ES1052883Y (es) Comedero para animales estabulizados.
ES1055109Y (es) Comedero perfeccionado para ganado.
ES1052052Y (es) Brida.
SE0200289D0 (sv) Självhäftande hästsko